Hemoglobinopathies Market Research Report Information by Type (Thalassemia (Alpha Thalassemia, Beta Thalassemia), Sickle Cell Disease and other Hb Variant Diseases), Treatment (Stem-cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, ACE inhibitors, Hydroxyurea), End User (Hospitals & Clinics, Diagnostics Laboratories and others) - Forecast till 2032

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Macroeconomic Indicators

4.5 Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Opportunities

5.4 Pricing Analysis

Chapter 6. Global Hemoglobinopathies Market, By Type

6.1 Introduction

6.2 Thalassemia

6.3.1 Alpha Thalassemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.2 Beta Thalassemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Sickle Cell Disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Other Hb Variants Diseases

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Hemoglobinopathies Market, By Treatment

7.1 Introduction

7.2 Stem-cell transplantation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Blood transfusions

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Analgesics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Antibiotics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 ACE inhibitors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Hydroxyurea

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Hemoglobinopathies Market, By End Users

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Diagnostics Laboratories

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Sanofi

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Sangamo Therapeutics Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Global Blood Therapeutics

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 bluebird bio Inc

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Emmaus Life Sciences Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Prolong Pharmaceuticals

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Celgene Corporation

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Alnylam Pharmaceuticals

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Gamida Cell

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Acceleron Pharma

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Mast Therapeutic

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 HemaQuest Pharmaceuticals

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Invenux

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Other

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Global Hemoglobinopathies Market

Chapter 13 Appendix

LIST OF TABLES

Table 1 Hemoglobinopathies Market Synopsis, 2020-2027

Table 2 Hemoglobinopathies Market Estimates and Forecast, 2020-2027(USD Million)

Table 3 Global Hemoglobinopathies Market, by Region, 2020-2027(USD Million)

Table 4 Global Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 5 Global Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 6 Global Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 7 North America: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 8 North America: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 9 North America: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 10 US: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 11 US: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 12 US: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 13 Canada: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 14 Canada: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 15 Canada: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 16 South America: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 17 South America: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 18 South America: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 19 Europe: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 20 Europe: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 21 Europe: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 22 Western Europe: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 23 Western Europe: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 24 Western Europe: Hemoglobinopathies Market, by End User, 2020-2027(USD Million)

Table 25 Eastern Europe: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 26 Eastern Europe: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 27 Eastern Europe: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 28 Asia-Pacific: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 29 Asia-Pacific: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 30 Asia-Pacific: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 31 Middle East & Africa: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 32 Middle East & Africa: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 33 Middle East & Africa: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Hemoglobinopathies Market

Figure 3 Market Dynamics for Global Hemoglobinopathies Market

Figure 4 Hemoglobinopathies Market Share, by Type, 2020

Figure 5 Hemoglobinopathies Market Share, by Treatment, 2020

Figure 6 Hemoglobinopathies Market Share, End User, 2020

Figure 7 Hemoglobinopathies Market Share, by Region, 2020

Figure 8 North America: Hemoglobinopathies Market Share, by Country, 2020

Figure 9 Europe: Hemoglobinopathies Market Share, by Country, 2020

Figure 10 Asia-Pacific: Hemoglobinopathies Market Share, by Country, 2020

Figure 11 Middle East & Africa: Hemoglobinopathies Market Share, by Region, 2020

Figure 12 Hemoglobinopathies Market: Company Share Analysis, 2020 (%)

Figure 13 Sanofi: Key Financials

Figure 14 Sanofi: Segmental Revenue

Figure 15 Sanofi: Geographical Revenue

Figure 16 Sangamo Therapeutics Inc.: Key Financials

Figure 17 Sangamo Therapeutics Inc.: Segmental Revenue

Figure 18 Sangamo Therapeutics Inc.: Geographical Revenue

Figure 19 Global Blood Therapeutics: Key Financials

Figure 20 Global Blood Therapeutics: Segmental Revenue

Figure 21 Global Blood Therapeutics: Geographical Revenue

Figure 22 bluebird bio Inc: Key Financials

Figure 23 bluebird bio Inc: Segmental Revenue

Figure 24 bluebird bio Inc: Geographical Revenue

Figure 25 Emmaus Life Sciences Inc.: Key Financials

Figure 26 Emmaus Life Sciences Inc.: Segmental Revenue

Figure 27 Emmaus Life Sciences Inc.: Geographical Revenue

Figure 28 Prolong Pharmaceuticals: Key Financials

Figure 29 Prolong Pharmaceuticals: Segmental Revenue

Figure 30 Prolong Pharmaceuticals: Geographical Revenue

Figure 31 Celgene Corporation: Key Financials

Figure 32 Celgene Corporation: Segmental Revenue

Figure 33 Celgene Corporation: Geographical Revenue

Figure 34 Alnylam Pharmaceuticals: Key Financials

Figure 35 Alnylam Pharmaceuticals: Segmental Revenue

Figure 36 Alnylam Pharmaceuticals: Geographical Revenue

Figure 37 Gamida Cell: Key Financials

Figure 38 Gamida Cell: Segmental Revenue

Figure 39 Gamida Cell: Geographical Revenue

Figure 40 Acceleron Pharma: Key Financials

Figure 41 Acceleron Pharma: Segmental Revenue

Figure 42 Acceleron Pharma: Geographical Revenue

Figure 43 Mast Therapeutic: Key Financials

Figure 44 Mast Therapeutic: Segmental Revenue

Figure 45 Mast Therapeutic: Geographical Revenue

Figure 46 HemaQuest Pharmaceuticals: Key Financials

Figure 47 HemaQuest Pharmaceuticals: Segmental Revenue

Figure 48 HemaQuest Pharmaceuticals: Geographical Revenue